Recent functional genomic efforts have identified specific molecular dependencies of aberrant AML gene expression, such as the requirement of DOT1L for the maintenance of MLL-rearranged leukemias, prompting the clinical development of DOT1L methyltransferase inhibitors for AML therapy6,7. This evidence concerns the gene DOT1L and acute myeloid leukemia.